Certain medications, though effective for their intended purposes, can cause significant cardiac side effects. Monitoring is essential to mitigate risks and ensure patient safety. Examples include:
- Chemotherapy Agents: Drugs like doxorubicin and trastuzumab are known to cause cardiotoxicity, leading to heart failure or arrhythmias (NCI, 2025).
- Antipsychotics: Medications such as haloperidol and olanzapine can prolong the QT interval, increasing the risk of life-threatening arrhythmias (APA, 2023).
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Long-term use of NSAIDs like ibuprofen is linked to an elevated risk of heart attack or stroke (AHA, 2024).
- Stimulants: Drugs prescribed for ADHD, such as amphetamines, can raise blood pressure and heart rate, posing risks for patients with underlying cardiac conditions (FDA, 2024).
DigiBeat offers a game-changing solution that enables the monitoring of cardiac health. Its advanced machine learning can detect subtle changes in heart sounds and rhythms, allowing for early intervention. For patients on high-risk medications, DigiBeat provides:
- Monitoring: Tracking heart function over time to identify early signs of cardiotoxicity.
- Remote Access: Allowing healthcare providers to review data and make timely adjustments to treatment plans.
- Personalized Insights: Leveraging machine learning to deliver patient-specific recommendations and alerts.
By integrating DigiBeat into the care regimen, healthcare providers can proactively manage the risks associated with these medications, improving outcomes and quality of life for patients.
- National Cancer Institute (NCI). (2025). Cardiotoxicity of Chemotherapy Agents. Retrieved from cancer.gov.
- American Psychiatric Association (APA). (2023). Cardiac Risks Associated with Antipsychotics. Psychiatry Journal.
- Food and Drug Administration (FDA). (2024). Stimulants and Cardiac Risks. Retrieved from fda.gov.
